echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > JiMu Biological Suprachoroidal Cavity Injection Therapy Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India

    JiMu Biological Suprachoroidal Cavity Injection Therapy Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 15th, JiMu Biotech announced that it has reached a license supplementary agreement with its partner Clearside Biomedical, Inc.


    ARVN001 is a patented suspension of the glucocorticoid triamcinolone acetonide, which can be administered to the suprachoroidal space (SCS®) through a patented suprachoroidal microinjector (SCS Microinjector®).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.